• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2020

report cover
  • 22 June 2020
  • Healthcare
  • 115 Pages
  • Report Code: 24LS-8450
  • Formate :   
Download FREE Report Sample Download PDF File

Benign Prostatic Hyperplasia Drugs -MARKET ADVISORY SERVICES

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type, the Benign Prostatic Hyperplasia (BPH) Drugs market is segmented into
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
The classification of Benign Prostatic Hyperplasia (BPH) Drugs includes Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors and Others. And the proportion of M Alpha-Blocker in 2019 is about 38%.

Segment by Application
Hospitals
Drugstores
Others
Benign Prostatic Hyperplasia (BPH) Drugs is widely used in Hospitals, Drugstores and Others. The most proportion of Benign Prostatic Hyperplasia (BPH) Drugs is used in Hospitals, and the proportion in 2019 is 48.97%.

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Regional Analysis
The Benign Prostatic Hyperplasia (BPH) Drugs market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Benign Prostatic Hyperplasia (BPH) Drugs market report are:
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

The major players in global Benign Prostatic Hyperplasia (BPH) Drugs market include:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
1.3.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2015-2026
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2015-2026
1.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2020 Versus 2026
1.5 Benign Prostatic Hyperplasia (BPH) Drugs Industry
1.6 Benign Prostatic Hyperplasia (BPH) Drugs Market Trends

2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Manufacturers
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2015-2020)
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2015-2020)
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Sites, Area Served, Product Type
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
2.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Benign Prostatic Hyperplasia (BPH) Drugs Players (Opinion Leaders)

3 Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
3.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.6.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.6.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.7.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Analysis by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2015-2020)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Market Share by Type (2015-2020)
4.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Analysis by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2015-2020)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2015-2020)

6 Company Profiles and Key Figures in Benign Prostatic Hyperplasia (BPH) Drugs Business
6.1 Eli Lilly
6.1.1 Corporation Information
6.1.2 Eli Lilly Description, Business Overview and Total Revenue
6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Eli Lilly Products Offered
6.1.5 Eli Lilly Recent Development
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description, Business Overview and Total Revenue
6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.2.4 GlaxoSmithKline Products Offered
6.2.5 GlaxoSmithKline Recent Development
6.3 Astellas Pharma
6.3.1 Astellas Pharma Corporation Information
6.3.2 Astellas Pharma Description, Business Overview and Total Revenue
6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Astellas Pharma Products Offered
6.3.5 Astellas Pharma Recent Development
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description, Business Overview and Total Revenue
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Sanofi Products Offered
6.4.5 Sanofi Recent Development
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description, Business Overview and Total Revenue
6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Pfizer Products Offered
6.5.5 Pfizer Recent Development
6.6 Abbott
6.6.1 Abbott Corporation Information
6.6.2 Abbott Description, Business Overview and Total Revenue
6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Abbott Products Offered
6.6.5 Abbott Recent Development
6.7 Allergan
6.6.1 Allergan Corporation Information
6.6.2 Allergan Description, Business Overview and Total Revenue
6.6.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Allergan Products Offered
6.7.5 Allergan Recent Development
6.8 TEVA
6.8.1 TEVA Corporation Information
6.8.2 TEVA Description, Business Overview and Total Revenue
6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.8.4 TEVA Products Offered
6.8.5 TEVA Recent Development
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Description, Business Overview and Total Revenue
6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Mylan Products Offered
6.9.5 Mylan Recent Development
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description, Business Overview and Total Revenue
6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.10.4 Novartis Products Offered
6.10.5 Novartis Recent Development
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Description, Business Overview and Total Revenue
6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
6.11.4 Merck Products Offered
6.11.5 Merck Recent Development

7 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Analysis
7.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
7.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
8.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers

9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis

10 Global Market Forecast
10.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2021-2026)
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2021-2026)
10.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2021-2026)
10.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026)
10.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026)
10.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026)
10.7 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026)
10.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2021-2026)
11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables

Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate Comparison by Type (2015-2026)

Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Comparison by Application: 2020 VS 2026

Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (M Units) (US$ Million) (2020 VS 2026)

Table 4. Global Key Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Covered in This Study

Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Manufacturers (2015-2020)

Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers (2015-2020)

Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Manufacturers (2015-2020)

Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2015-2020)

Table 9. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) of Key Manufacturers (2015-2020)

Table 10. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Sales Sites and Area Served

Table 11. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Types

Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2019)

Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 15. Main Points Interviewed from Key Benign Prostatic Hyperplasia (BPH) Drugs Players

Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Region (2015-2020)

Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020)

Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) by Region (2015-2020)

Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2015-2020)

Table 20. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units)

Table 21. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)

Table 22. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million)

Table 23. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)

Table 24. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units)

Table 25. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)

Table 26. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million)

Table 27. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)

Table 28. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2015-2020) (M Units)

Table 29. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020)

Table 30. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2015-2020) (US$ Million)

Table 31. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2015-2020)

Table 32. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units)

Table 33. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)

Table 34. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million)

Table 35. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)

Table 36. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2015-2020) (M Units)

Table 37. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2015-2020)

Table 38. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2015-2020) (US$ Million)

Table 39. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2015-2020)

Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020)

Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2015-2020)

Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) by Type (2015-2020)

Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2015-2020)

Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2015-2020)

Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)

Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)

Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Application (2015-2020)

Table 48. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 49. Eli Lilly Description and Business Overview

Table 50. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 51. Eli Lilly Main Product

Table 52. Eli Lilly Recent Development

Table 53. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 54. GlaxoSmithKline Corporation Information

Table 55. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 56. GlaxoSmithKline Main Product

Table 57. GlaxoSmithKline Recent Development

Table 58. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 59. Astellas Pharma Corporation Information

Table 60. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 61. Astellas Pharma Main Product

Table 62. Astellas Pharma Recent Development

Table 63. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 64. Sanofi Corporation Information

Table 65. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 66. Sanofi Main Product

Table 67. Sanofi Recent Development

Table 68. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 69. Pfizer Corporation Information

Table 70. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 71. Pfizer Main Product

Table 72. Pfizer Recent Development

Table 73. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 74. Abbott Corporation Information

Table 75. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 76. Abbott Main Product

Table 77. Abbott Recent Development

Table 78. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 79. Allergan Corporation Information

Table 80. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 81. Allergan Main Product

Table 82. Allergan Recent Development

Table 83. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 84. TEVA Corporation Information

Table 85. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 86. TEVA Main Product

Table 87. TEVA Recent Development

Table 88. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 89. Mylan Corporation Information

Table 90. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 91. Mylan Main Product

Table 92. Mylan Recent Development

Table 93. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 94. Novartis Corporation Information

Table 95. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 96. Novartis Main Product

Table 97. Novartis Recent Development

Table 98. Merck Benign Prostatic Hyperplasia (BPH) Drugs Corporation Information

Table 99. Merck Corporation Information

Table 100. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)

Table 101. Merck Main Product

Table 102. Merck Recent Development

Table 103. Sales Base and Market Concentration Rate of Raw Material

Table 104. Key Suppliers of Raw Materials

Table 105. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List

Table 106. Benign Prostatic Hyperplasia (BPH) Drugs Customers List

Table 107. Market Key Trends

Table 108. Key Opportunities and Drivers: Impact Analysis (2021-2026)

Table 109. Key Challenges

Table 110. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Forecast by Type (2021-2026)

Table 111. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2021-2026)

Table 112. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) Forecast by Type (2021-2026)

Table 113. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) Market Share Forecast by Type (2021-2026)

Table 114. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Forecast by Application (2021-2026)

Table 115. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) Forecast by Application (2021-2026)

Table 116. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Forecast by Region (2021-2026)

Table 117. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2021-2026)

Table 118. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2021-2026) (US$ Million)

Table 119. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Region (2021-2026)

Table 120. Research Programs/Design for This Report

Table 121. Key Data Information from Secondary Sources

Table 122. Key Data Information from Primary Sources

List of Figures

Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Drugs

Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type: 2020 VS 2026

Figure 3. Alpha-Blocker Product Picture

Figure 4. Phosphodiesterase Type-5 Inhibitors Product Picture

Figure 5. Others Product Picture

Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application: 2020 VS 2026

Figure 7. Hospitals

Figure 8. Drugstores

Figure 9. Others

Figure 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size 2015-2026 (US$ Million)

Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Capacity (M Units) (2015-2026)

Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Region: 2020 Versus 2026

Figure 13. Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers in 2020

Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers in 2019

Figure 15. The Global 5 and 10 Largest Players: Market Share by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2019

Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019

Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020)

Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2019

Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2015-2020)

Figure 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2019

Figure 21. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2019

Figure 22. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019

Figure 23. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 24. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 25. Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 26. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 27. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2019

Figure 28. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019

Figure 29. Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 30. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 31. France Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 32. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 33. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 34. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 35. Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 36. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 37. Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 38. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 39. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2019

Figure 40. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2019

Figure 41. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 42. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 43. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 44. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 45. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 46. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 47. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 48. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 49. Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 50. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 51. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 52. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 53. Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 54. Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 55. Thailand Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 56. Thailand Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 57. Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 58. Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 59. Philippines Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 60. Philippines Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 61. Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 62. Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 63. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2019

Figure 64. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019

Figure 65. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 66. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 67. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 68. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 69. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 70. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 71. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2019

Figure 72. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2019

Figure 73. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 74. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 75. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 76. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 77. UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2020) (M Units)

Figure 78. UAE Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 79. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2015-2020)

Figure 80. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2019

Figure 81. Revenue Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2015-2020)

Figure 82. Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2019

Figure 83. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth by Type (2015-2020) (M Units)

Figure 84. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)

Figure 85. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2019

Figure 86. Global Revenue Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2015-2020)

Figure 87. Global Revenue Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2020

Figure 88. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018

Figure 89. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018

Figure 90. Astellas Pharma Total Revenue (US$ Million): 2019 Compared with 2018

Figure 91. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018

Figure 92. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018

Figure 93. Abbott Total Revenue (US$ Million): 2019 Compared with 2018

Figure 94. Allergan Total Revenue (US$ Million): 2019 Compared with 2018

Figure 95. TEVA Total Revenue (US$ Million): 2019 Compared with 2018

Figure 96. Mylan Total Revenue (US$ Million): 2019 Compared with 2018

Figure 97. Novartis Total Revenue (US$ Million): 2019 Compared with 2018

Figure 98. Merck Total Revenue (US$ Million): 2019 Compared with 2018

Figure 99. Price Trend of Key Raw Materials

Figure 100. Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs

Figure 101. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

Figure 102. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis

Figure 103. Channels of Distribution

Figure 104. Distributors Profiles

Figure 105. Porter's Five Forces Analysis

Figure 106. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) and Growth Rate Forecast (2021-2026)

Figure 107. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)

Figure 108. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) and Growth Rate Forecast (2021-2026)

Figure 109. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)

Figure 110. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) and Growth Rate Forecast (2021-2026)

Figure 111. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)

Figure 112. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) and Growth Rate Forecast (2021-2026)

Figure 113. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)

Figure 114. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) and Growth Rate Forecast (2021-2026)

Figure 115. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026)

Figure 116. Bottom-up and Top-down Approaches for This Report

Figure 117. Data Triangulation

Figure 118. Key Executives Interviewed

Eli Lilly

GlaxoSmithKline

Astellas Pharma

Sanofi

Pfizer

Abbott

Allergan

TEVA

Mylan

Novartis

Merck

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $2378

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase